These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
421 related articles for article (PubMed ID: 21792136)
1. Use of intravenous conivaptan in neurosurgical patients with hyponatremia from syndrome of inappropriate antidiuretic hormone secretion. Potts MB; DeGiacomo AF; Deragopian L; Blevins LS Neurosurgery; 2011 Aug; 69(2):268-73. PubMed ID: 21792136 [TBL] [Abstract][Full Text] [Related]
2. Use of conivaptan for management of hyponatremia following surgery for Cushing's disease. Breshears JD; Jiang B; Rowland NC; Kunwar S; Blevins LS Clin Neurol Neurosurg; 2013 Nov; 115(11):2358-61. PubMed ID: 24041963 [TBL] [Abstract][Full Text] [Related]
3. A novel vasopressin dual V1A/V2 receptor antagonist, conivaptan hydrochloride, improves hyponatremia in rats with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Wada K; Matsukawa U; Fujimori A; Arai Y; Sudoh K; Sasamata M; Miyata K Biol Pharm Bull; 2007 Jan; 30(1):91-5. PubMed ID: 17202666 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic effect of conivaptan bolus dosing in hyponatremic neurosurgical patients. Marik PE; Rivera R Pharmacotherapy; 2013 Jan; 33(1):51-5. PubMed ID: 23307545 [TBL] [Abstract][Full Text] [Related]
5. Conivaptan for hyponatremia in the neurocritical care unit. Wright WL; Asbury WH; Gilmore JL; Samuels OB Neurocrit Care; 2009; 11(1):6-13. PubMed ID: 19003543 [TBL] [Abstract][Full Text] [Related]
6. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Zeltser D; Rosansky S; van Rensburg H; Verbalis JG; Smith N; Am J Nephrol; 2007; 27(5):447-57. PubMed ID: 17664863 [TBL] [Abstract][Full Text] [Related]
7. Intravenous conivaptan for the treatment of hyponatraemia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a single-centre experience. Velez JC; Dopson SJ; Sanders DS; Delay TA; Arthur JM Nephrol Dial Transplant; 2010 May; 25(5):1524-31. PubMed ID: 20064953 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness and Tolerability of Conivaptan and Tolvaptan for the Treatment of Hyponatremia in Neurocritically Ill Patients. Der-Nigoghossian C; Lesch C; Berger K Pharmacotherapy; 2017 May; 37(5):528-534. PubMed ID: 28295447 [TBL] [Abstract][Full Text] [Related]
9. Conivaptan bolus dosing for the correction of hyponatremia in the neurointensive care unit. Murphy T; Dhar R; Diringer M Neurocrit Care; 2009; 11(1):14-9. PubMed ID: 19123060 [TBL] [Abstract][Full Text] [Related]
10. Use of conivaptan to allow aggressive hydration to prevent tumor lysis syndrome in a pediatric patient with large-cell lymphoma and SIADH. Rianthavorn P; Cain JP; Turman MA Pediatr Nephrol; 2008 Aug; 23(8):1367-70. PubMed ID: 18437428 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. Ghali JK; Koren MJ; Taylor JR; Brooks-Asplund E; Fan K; Long WA; Smith N J Clin Endocrinol Metab; 2006 Jun; 91(6):2145-52. PubMed ID: 16522696 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. Annane D; Decaux G; Smith N; Am J Med Sci; 2009 Jan; 337(1):28-36. PubMed ID: 19057376 [TBL] [Abstract][Full Text] [Related]
13. Use of conivaptan for refractory syndrome of inappropriate secretion of antidiuretic hormone in a pediatric patient. Peters S; Kuhn R; Gardner B; Bernard P Pediatr Emerg Care; 2013 Feb; 29(2):230-2. PubMed ID: 23546432 [TBL] [Abstract][Full Text] [Related]
14. Rapidity of Correction of Hyponatremia Due to Syndrome of Inappropriate Secretion of Antidiuretic Hormone Following Tolvaptan. Morris JH; Bohm NM; Nemecek BD; Crawford R; Kelley D; Bhasin B; Nietert PJ; Velez JCQ Am J Kidney Dis; 2018 Jun; 71(6):772-782. PubMed ID: 29478867 [TBL] [Abstract][Full Text] [Related]
15. Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials. Gralla RJ; Ahmad F; Blais JD; Chiodo J; Zhou W; Glaser LA; Czerwiec FS Cancer Med; 2017 Apr; 6(4):723-729. PubMed ID: 28251822 [TBL] [Abstract][Full Text] [Related]
16. [Vasopressin antagonists in treatment of hyponatremia]. Olszewski W; Głuszek J Pol Arch Med Wewn; 2007 Aug; 117(8):356-62. PubMed ID: 18018383 [TBL] [Abstract][Full Text] [Related]
18. Conivaptan for treatment of hyponatremia in neurologic and neurosurgical adults. Buckley MS; Patel SA; Hattrup AE; Kazem NH; Jacobs SC; Culver MA Ann Pharmacother; 2013 Sep; 47(9):1194-200. PubMed ID: 24259735 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of 30-minute infusions of conivaptan in euvolemic and hypervolemic hyponatremia. Koren MJ; Hamad A; Klasen S; Abeyratne A; McNutt BE; Kalra S Am J Health Syst Pharm; 2011 May; 68(9):818-27. PubMed ID: 21515866 [TBL] [Abstract][Full Text] [Related]
20. Tolvaptan Treatment in Children with Chronic Hyponatremia due to Inappropriate Antidiuretic Hormone Secretion: A Report of Three Cases. Tuli G; Tessaris D; Einaudi S; De Sanctis L; Matarazzo P J Clin Res Pediatr Endocrinol; 2017 Sep; 9(3):288-292. PubMed ID: 28515029 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]